Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
FUJIFILM Toyama Chemical Co., Ltd.
With
Alzheimer's Disease Cooperative Study (ADCS)
Age
55–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female (post-menopausal or surgically sterile)
Patients with Mild to moderate Alzheimer's disease who are receiving donepezil (Aricept®) or rivastigmine transdermal system (Exelon® Patch), . Memantine (Namenda®) is allowed only when prescribed in combination with donepezil or rivastigmine transdermal system.
Age 55 to 85 inclusive
Patients must be living in the community
Patients must have an eligible informant or study partner (caregiver)
Patients and eligible informant or study partner (caregiver) must be able to read and understand English.
Informed consent obtained from both the patient and the caregiver
You may not be if
Patients with clinically significant cardiac, hepatic or renal impairment
Patient have a dementia not of the Alzheimer's type etc (According to the protocol)
Patients who are taking any drug other than donepezil or rivastigmine transdermal system for Alzheimer's disease, including olal rivastigmine (Exelon®), galantamine (Razadyne®)
Clareo Health | Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
